EntreMed reports higher loss in 4Q

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported a fourth-quarter net loss of $1.3 million, or 5 cents per diluted share, versus a net loss of $360,000, or 2 cents per diluted share, for the prior-year period.

Leave a Reply

Your email address will not be published. Required fields are marked *